Last updated on August 2018

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC


Brief description of study

The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent or in combination with INC280 administered orally in adult patients with advanced hepatocellular carcinoma (HCC).

Clinical Study Identifier: NCT02795429

Find a site near you

Start Over